ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.05 by 60 percent. This is a 81.82 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $268.062 million which missed the analyst consensus estimate of $280.710 million by 4.51 percent. This is a 9.72 percent increase over sales of $244.317 million the same period last year.